Nasopharyngeal Carcinoma
A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.
Drugs by status
Approved for this indication (1)
Phase 4 trials (6)
Phase 3 trials (45)
- amifostine
- atezolizumab
- autologous ebv specific cytotoxic t lymphocytes
- fluorouracil
- paclitaxel
- lapatinib
- hydroxyurea
- epirubicin
- Filgrastim
- nivolumab
- mitomycin
- leucovorin
- mupirocin
- oprelvekin
- endostatin
- celecoxib
- bevacizumab
- cetuximab
- tumor necrosis factor
- capecitabine
- human fecal microbiota
- l-epigallocatechin
- adebrelimab
- methotrexate
- docetaxel
- nedaplatin
- lobaplatin
- teplizumab
- prednisolone
- mitoxantrone
- +15 more
Phase 2 trials (102)
- icotinib
- ferric derisomaltose
- 2-fluoropropionyl-labeled pegylated dimeric rgd peptide
- decitabine
- methylprednisolone
- denosumab
- galunisertib
- anlotinib
- allogeneic natural killer cells
- avelumab
- urea
- bmx-001
- irinotecan
- temsirolimus
- edaravone
- prednisone
- valproic acid
- doxorubicin
- durvalumab
- e10a
- famitinib
- ficlatuzumab
- fluzoparib
- hetrombopag olamine
- aldesleukin
- epacadostat
- pembrolizumab
- msk-2206
- niraparib
- opb-111077
- +72 more
Phase 1 trials (34)
- azacitidine
- anti cd45 monoclonal antibody
- astx660
- lenalidomide
- donafenib
- opb-51602
- panobinostat
- atazanavir
- sitravatinib
- everolimus
- birinapant
- dnr.npc-specific t cells
- epstein-barr virus cytotoxic t lymphocytes
- genetically modified ctls
- lmp-specific cytotoxic t-lymphocytes
- mabel ctls
- aprepitant
- floxuridine
- dexamethasone
- bgb-a445
- xmab20717
- inbrx-105
- incb099318
- xmab22841
- xmab23104
- dky709
- anrotenib
- incb099280
- nkg2dl-targetting chimeric antigen receptor-grafted gamma delta t cell
- apg-5918
- +4 more
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (81)
- BeOne Medicines
- Hengrui Therapeutics, Inc.
- Innovent Biologics (Suzhou) Co. Ltd.
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Tessa Therapeutics
- National Cancer Institute (NCI)
- Nanning Second People's Hospital
- Huazhong University of Science and Technology
- Cancer Hospital of Guizhou Province
- Central South University
- Chang Gung University
- Changhua Christian Hospital
- Chung Shan Medical University
- Chimei Medical Center
- First People's Hospital of Foshan
- Guangxi Medical University
- Guangzhou Medical University
- Hacettepe University
- Harbin Medical University
- Hong Kong Nasopharyngeal Cancer Study Group Limited
- Kaohsiung Medical University
- Jilin Provincial Tumor Hospital
- Jinhua Central Hospital
- Kunming Medical University
- Nanjing Medical University
- National Cheng Kung University
- NRG Oncology
- Sichuan University
- Sutter Health
- University of Kansas
- +51 more
Organization Involved with Phase 2 Indications (81)
- Incyte
- Celgene
- Bristol-Myers Squibb
- Roche
- AstraZeneca
- Merck
- Merck Serono
- Eli Lilly
- Genentech
- Merck KGaA
- Pfizer
- Sanofi
- Novartis
- Atara Biotherapeutics
- Betta Pharmaceuticals Co.,Ltd.
- Simcere Pharmaceutical Co., Ltd
- Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
- Shanghai Junshi Bioscience Co.,Ltd.
- Guiyang Medical University
- Baylor University
- Case Western Reserve University
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- Temple University
- University of Washington
- Gruppo Oncologico del Nord-Ovest
- King Faisal University
- Johns Hopkins University
- Nanjing University
- +51 more
Organization Involved with Phase 1 Indications (19)
- Cleveland BioLabs
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Agennix
- Otsuka
- TTY Biopharm
- The EMMES Corporation
- National Institutes of Health (NIH)
- AIDS Malignancy Consortium
- Cancer and Leukemia Group B (CALGB)
- Cancer Research UK
- Hoosier Cancer Research Network
- Vanderbilt University
- Xencor
- Universitair Ziekenhuis Gent
- Shin Nippon Biomedical Laboratories
- Washington University in St. Louis
- ICON
- CytoMed Therapeutics Pte Ltd
- argenx
Organization Involved with Other Experimental Indications (5)